Bicycle Therapeutics PLC (BCYC) stock
BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3080% below fair value
$3.11−0.09 (-2.81%)
Close on Nov 18, 2026Market cap $217.99MP/E –Yield 0.00%
Bicycle Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Bicycle Therapeutics's revenue for the twelve months ending Sep 30, 2026 was $83.53M, up 194.7% year over year. For fiscal 2025 it was $72.59M, up 105.8% from the year before. The highest annual figure on record is $72.59M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.59M | +105.8% |
| FY2024 | Dec 31, 2024 | $35.28M | +30.8% |
| FY2023 | Dec 31, 2023 | $26.98M | +86.5% |
| FY2022 | Dec 31, 2022 | $14.46M | +23.6% |
| FY2021 | Dec 31, 2021 | $11.70M | +12.6% |
| FY2020 | Dec 31, 2020 | $10.39M | -24.7% |
| FY2019 | Dec 31, 2019 | $13.80M | +93.4% |
| FY2018 | Dec 31, 2018 | $7.14M | +246.4% |
| FY2017 | Dec 31, 2017 | $2.06M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $34.06M | +190.2% |
| Q2 FY2026 | Jun 30, 2026 | $629.00K | -78.5% |
| Q1 FY2026 | Mar 31, 2026 | $887.00K | -91.1% |
| Q4 FY2025 | Dec 31, 2025 | $47.96M | +1193.3% |
| Q3 FY2025 | Sep 30, 2025 | $11.73M | +338.5% |
| Q2 FY2025 | Jun 30, 2025 | $2.92M | -68.8% |
| Q1 FY2025 | Mar 31, 2025 | $9.98M | -48.9% |
| Q4 FY2024 | Dec 31, 2024 | $3.71M | -30.4% |
| Q3 FY2024 | Sep 30, 2024 | $2.68M | -50.0% |
| Q2 FY2024 | Jun 30, 2024 | $9.36M | -17.9% |
| Q1 FY2024 | Mar 31, 2024 | $19.53M | +298.9% |
| Q4 FY2023 | Dec 31, 2023 | $5.33M | +67.4% |
| Q3 FY2023 | Sep 30, 2023 | $5.35M | +76.1% |
| Q2 FY2023 | Jun 30, 2023 | $11.40M | +160.3% |
| Q1 FY2023 | Mar 31, 2023 | $4.90M | +26.8% |
| Q4 FY2022 | Dec 31, 2022 | $3.19M | -15.5% |
| Q3 FY2022 | Sep 30, 2022 | $3.04M | -29.8% |
| Q2 FY2022 | Jun 30, 2022 | $4.38M | +145.3% |
| Q1 FY2022 | Mar 31, 2022 | $3.86M | +113.5% |
| Q4 FY2021 | Dec 31, 2021 | $3.77M | -2.0% |
| Q3 FY2021 | Sep 30, 2021 | $4.33M | +12.8% |
| Q2 FY2021 | Jun 30, 2021 | $1.79M | +13.6% |
| Q1 FY2021 | Mar 31, 2021 | $1.81M | +60.1% |
| Q4 FY2020 | Dec 31, 2020 | $3.85M | -27.1% |
| Q3 FY2020 | Sep 30, 2020 | $3.84M | +525.7% |
| Q2 FY2020 | Jun 30, 2020 | $1.57M | +3.2% |
| Q1 FY2020 | Mar 31, 2020 | $1.13M | -82.3% |
| Q4 FY2019 | Dec 31, 2019 | $5.28M | +399.6% |
| Q3 FY2019 | Sep 30, 2019 | $614.00K | -61.9% |
| Q2 FY2019 | Jun 30, 2019 | $1.52M | -8.4% |
| Q1 FY2019 | Mar 31, 2019 | $6.38M | +127.4% |
| Q4 FY2018 | Dec 31, 2018 | $1.06M | – |
| Q3 FY2018 | Sep 30, 2018 | $1.61M | – |
| Q2 FY2018 | Jun 30, 2018 | $1.66M | – |
| Q1 FY2018 | Mar 31, 2018 | $2.81M | – |
See a number that looks wrong?